Table 1

Patient characteristics

ID	Sex	Age	Rai stage	Mutation status	ALC (×10⁹/L)	%CD5⁺ cd19⁺	Cytogenetics	TP53 mutation	Treatment
1	Male	67	II	Mutated	149	93,2	Del17p, trisomy 13, t(8;14)	ND	F, Chl
2	Male	68	I	Unmutated	NA	90	Del13q14	ND	R-CHOP, F
3	Female	55	ND	Unmutated	46,6	97,2	ND	ND	F, other lines unknown
4	Male	42	ND	Unmutated	287	99,7	Del11q	ND	Chl
5	Male	75	I	Unmutated	127	93	Del13q14	ND	No
6	Male	65	ND	ND	162,8	97,8	ND	ND	F, other lines unknown
7	Male	76	III	Unmutated	120	91	Del11q	ND	Chl, CVP, F
8	Male	81	NA	ND	136	97	Del13q14	ND	Chl, F
9	Female	63	0	Polyclonal	34,6	92,2	Normal	ND	No
10	Male	59	NA	Mutated	155	87,9	Del17p, trisomy 12	ND	Chl, R-CVP, FCR, R
11	Male	70	NA	Mutated	322,6	100	Del13q14	ND	Chl, FC,
12	Male	27	NA	Unmutated	160,5	93,8	Del13q14, Del11q, loss 6q	TP53 WT	No
13	Male	60	0	Mutated	56,5	95,2	ND	ND	No
14	Male	75	II	ND	73,4	96,6	Del13q14	TP53 WT	No
15	Male	52	I	Unmutated	99,9	91,1	Del17p, loss 5q, 5q, 6 p, 10q, 13q, 14q, 15q, 18 p, Gain 10q, 12q,	ND	FCR
16	Male	70	NA	Unmutated	422	92,8	Del17p	ND	Chl, CVP, FCR
17	Female	75	0	ND	28,5	92,9	ND	ND	No
18	Female	71	I	Mutated	31,7	90,5	ND	ND	No
19	Female	75	0	Mutated	43,4	94,1	ND	ND	No
20	Male	77	II	Mutated	68,4	95,2	Del13q14	TP53 WT	No
21	Male	62	0	Mutated	80,1	92,1	Del13q14	TP53 WT	No
22	Female	60	0	Unmutated	65,3	91,2	Trisomy 12	TP53 WT	No
23	Male	75	NA	Mutated	84,1	91,8	ND	ND	No
24	Female	73	I	Mutated	36,9	89,9	ND	ND	No
25	Female	63	I	Mutated	110,3	92,6	Del13q14, Trisomy 12	ND	No
26	Male	63	0	Unmutated	250,91	97,6	Del11q	ND	No
27	Female	51	II	Mutated	122,75	92,4	Del13q14	TP53 WT	Chl, Of
28	Female	79	0	Mutated	83,8	93,5	ND	TP53 WT	No
29	Male	67	IV	Unmutated	333,7	96,8	Normal	TP53 WT	No
30	Female	54	I	Mutated	91,8	90,99	loss X	TP53 WT	No
31	Male	82	NA	Unmutated	34,6	93,74	ND	ND	No
32	Male	69	II	Unmutated	41,8	94,04	Del13q14, Del11q	TP53 WT	No
33	Male	63	0	ND	44,6	91,3	ND	ND	No
34	Female	73	0	Mutated	20,9	92,08	Del13q14	TP53 WT	No
35	Female	91	I	ND	68,5	92,92	ND	ND	No
36	Female	69	0	Mutated	58,51	92,26	Del13q14	ND	No
37	Male	66	I	Mutated	73,41	91,98	Normal	ND	No
38	Female	80	0	Unmutated	37,29	90,23	ND	ND	No
39	Female	86	I	Mutated	43,14	95,36	ND	ND	No
40	Male	77	0	Mutated	52,29	92,97	Del13q14, 14q32-rearrangement	ND	No
41	Male	70	0	ND	74,11	97,29	ND	ND	No
42	Female	67	0	ND	95,69	94,07	ND	ND	No
43	Male	82	ND	ND	83,66	91,85	ND	ND	No
44	Male	66	ND	ND	49,6	95,08	ND	ND	No
45	Female	54	ND	Mutated	76,84	94,52	ND	ND	No
46	Female	71	II	Unmutated	125,55	96,36	Del13q14	TP53 mut	Chl +R, Venetoclax (resistant)
47	Male	80	I	ND	65,7	94	Del13q14	TP53 mut	Chl, Ibr (resistant)
48	Male	61	ND	ND	76,65	91,7	Del17p	ND	R-CVP, FCR, Ibr (resistant)
49	Male	66	III	ND	114,82	96,39	Del13q14, Del17p	TP53 mut	FCR
50	Male	70	ND	Unmutated	36,48	87,57	Del17p, Del11q, gain of 3p14,3p14,1, 11q24,2q25	TP53 mut	No

Treatment indications were in accordance with IWCLL criteria. Patients with no treatments were in a steady state under a ‘watch and wait’ regimen. Deletion of 17 p was determined by CGH-array. TP53 mutations were determined by Sanger sequencing. Chemorefractory samples were defined according to IWCLL 2008 criteria and were marked as refractory when patients did not respond or relapsed ≤6 months after fludarabine treatment. Ibrutinib and venetoclax refractory samples were obtained from patients that had an IWCLL-defined progression under maintenance treatment with ibrutinib or venetoclax.
ALC, Absolute leukocyte count; Chl, chlorambucil; F, fludarabine; FCR, fludarabine, cyclophosphamide and rituximab; Ibr, ibrutinib; ND, not determined; Of, ofatumumab; R, rituximab; R-CHOP, rituximab cyclophosphamide, doxorubicin, vincristine and prednisone; R-CVP, rituximab cyclophosphamide, vincristin and prednisone; WT, wild type.